Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.71 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28487533 | 0.83 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL246112 | 0.83 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2089678 | 0.83 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL3180021 | 0.83 | CYP2A6 (1.00) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2094708 | 0.83 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL156931 | 0.83 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2949120 | 0.83 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL31673840 | 0.83 | CYP2A6 (1.00) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| Hydrochloric Acid SCHEMBL3575805 | 0.81 | CYP2A6 (0.96) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL4324624 | 0.80 | CYP2A6 (0.75) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518022-A | Aromatic (hetero) cyclic ether compound with insecticidal activity and preparation method and application thereof | 华东理工大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020156512-A1 | AROMATIC (HETERO)CYCLIC ETHER COMPOUND HAVING INSECTICIDAL ACTIVITY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 华东理工大学 | 2020-08-06 | — | — | WO | disclosed |
| EP-1756096-B1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-7485652-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | DEHMLOW HENRIETTA | 2007-05-03 | — | — | US | disclosed |
| EP-1756096-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105791-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | CYP2A6 158/4885KEAP1 1072/4885NFE2L2 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.